Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

NCT04820751 is registered in ClinicalTrials.gov with Ciusss de L'Est de l'Île de Montréal as lead sponsor.

NCT NCT04820751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04820751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Phase
Phase 3
Overall status
Unknown status
Start date
April 10, 2021
Completion date
January 1, 2022
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

platelet dysfunction, serotonin syndrome, viral pneumonia